Skip to main content

Advertisement

SpringerLink
Log in

Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer

  • Published:
Current Colorectal Cancer Reports

Abstract

Both irinotecan and oxaliplatin have demonstrated important clinical activity in metastatic colorectal cancer. Although they appear to have similar activity in metastatic disease, only oxaliplatin has demonstrated efficacy in the adjuvant setting. Despite a survival advantage of single agent irinotecan in the second-line metastatic setting and a survival advantage for irinotecan added to first-line metastatic treatment, irinotecan has failed to show a survival or disease-free survival benefit in the adjuvant setting, and at the present time there is no role for irinotecan in the adjuvant treatment of colon cancer. In contradistinction, the addition of oxaliplatin to 5-fluorouracil/leucovorin has improved disease-free survival in two large randomized adjuvant trials. Data for overall survival in these trials have not yet demonstrated statistical significance but are expected to with maturation. Oxaliplatin/5-fluorouracil/ leucovorin should, therefore, be regarded as a reference standard for adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rothenberg ML, Eckardt JR, Kuhn JG, et al.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.J Clin Oncol 1996, 14:1128–1135.

    PubMed  CAS  Google Scholar 

  2. Rothenberg ML, Cox JV, DeVore RF, et al.: A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma Cancer 1999, 85:786–795.

    Article  PubMed  CAS  Google Scholar 

  3. Rougier P, Bugat R, Douillard JY, et al.: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.J Clin Oncol 1997, 15:251–260.

    PubMed  CAS  Google Scholar 

  4. Rougier P, Van Cutsem E, Bajetta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.Lancet 1998, 352:1407–1412.

    Article  PubMed  CAS  Google Scholar 

  5. Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 1998, 352:1413–1418.

    Article  PubMed  CAS  Google Scholar 

  6. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.N Engl J Med 2000, 343:905–914. Pivotal trial demonstrating the role of irinotecan in first-line therapy of advanced colorectal cancer, leading to its FDA- approved indication.

    Article  PubMed  CAS  Google Scholar 

  7. Douillard JY, Cunningham D, Roth AD, etal.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.Lancet 2000, 355:1041–1047. Pivotal trial demonstrating the role of irinotecan in first-line therapy of advanced colorectal cancer, leading to its FDA- approved indication.

    Article  PubMed  CAS  Google Scholar 

  8. Kohne CH, Van Cutsem E, Wils JA et al.: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study 40986.Proc Am Soc Clin Oncol 2003, 22:254.

    Google Scholar 

  9. Rothenberg ML, Meropol NJ, Poplin EA, et al.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19:3801–3807.

    PubMed  CAS  Google Scholar 

  10. Miller L, Emanuel D, Elfring G, et al.: 60-day, all-cause mortality with first-line irinotecan/ fluorouracil/leucovorin (IFL) or fluorouracil/leucovorin (FL) for metastatic colorectal cancer (MCRC).Proc Am Soc Clin Oncol 2002, 21:515.

    Google Scholar 

  11. Raymond E, Buquet-Fagot C, Djelloul S, et al.: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.Anticancer Drugs 1997, 8:876–885.

    Article  PubMed  CAS  Google Scholar 

  12. Machover D, Diaz-Rubio E, de Gramont A, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95–8, 1996.

    PubMed  CAS  Google Scholar 

  13. Maindrault-Goebel F, de Gramont A, Louvet C, et al.: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).Ann Oncol 2000, 11:1477–1483.

    Article  PubMed  CAS  Google Scholar 

  14. Andre T, Louvet C, Maindrault-Goebel F, et al.: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999, 35:1343–1347.

    Article  PubMed  CAS  Google Scholar 

  15. Maindrault-Goebel F, Louvet C, Andre T, et al.: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999,35:1338–1342.

    Article  PubMed  CAS  Google Scholar 

  16. Maindrault-Goebel F, de Gramont A, Louvet C, et al.: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001, 37:1000–1005.

    Article  PubMed  CAS  Google Scholar 

  17. Martoni A, Mini E, Pinto C, et al.: Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol 2001, 12:519–524.

    Article  PubMed  CAS  Google Scholar 

  18. Chau I, Webb A, Cunningham D, et al.: Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 2001, 85:1258–64.

    Article  PubMed  CAS  Google Scholar 

  19. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998, 16:301–308.

  20. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23–30. Pivotal trial demonstrating the first-line role of FOLFOX in advanced colorectal cancer.

    Article  PubMed  CAS  Google Scholar 

  21. Tournigand C, Cervantes A, Figer A, etal.: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006, 24:394–400.

    Article  PubMed  CAS  Google Scholar 

  22. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229–237.

    Article  PubMed  CAS  Google Scholar 

  23. Colucci G, Gebbia V, Paoletti G, et al.: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005, 23:4866–4875.

    Article  PubMed  CAS  Google Scholar 

  24. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21:2059–2069.

    Article  PubMed  CAS  Google Scholar 

  25. Rothenberg ML, Oza AM, Burger B, et al.: Final results of a phase III trial of 5-FU/Leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU and leucovorin. Proc Am Soc Clin Oncol 2003, 22:A-1011.

    Google Scholar 

  26. Gowda A, Goel R, Berdzik J, et al.: Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004, 18:1671–1676, 1680, 1683-1684.

    Google Scholar 

  27. Seymour MT: Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135- patient randomized trial in advanced colorectal cancer (ACRC). ProcAm Soc Clin Oncol 2005, 23:3518.

    Google Scholar 

  28. Cassidy J, Tabernero J, Twelves C, et al.: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004, 22:2084–2091.

    Article  PubMed  CAS  Google Scholar 

  29. Twelves CJ, Butts CA, Cassidy J, et al.: Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005, 5:101–107.

    Article  PubMed  Google Scholar 

  30. Park SH, Bang SM, Cho EK, et al.: First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 2004, 66:353–357.

    Article  PubMed  CAS  Google Scholar 

  31. Scheithauer W, Kornek GV, Raderer M, etal.: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003, 21:1307–1312.

    Article  PubMed  CAS  Google Scholar 

  32. Schalhorn A, Ludwig F, Quietzsch D, et al.: Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): the FIRE-Trial. Proc Am Soc Clin Oncol 2005, 23:3516.

    Google Scholar 

  33. Becouarn Y, Gamelin E, Coudert B, et al.: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001, 19:4195–4201.

    PubMed  CAS  Google Scholar 

  34. Stathopoulos GP, Rigatos SK, Stathopoulos JG, et al.: Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Am J Clin Oncol 2005, 28:565–569.

    Article  PubMed  CAS  Google Scholar 

  35. Falcone A, Masi G, Allegrini G, et al.: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.J Clin Oncol 2002, 20:4006–4014.

    Article  PubMed  CAS  Google Scholar 

  36. Harba A, Peinert S, Grothe W, et al.: Weekly administration of 5-fluorouracil (5-FU), folinic acid (FA), oxaliplatin (L-OHP) and irinotecan (CPT-11) [FUFOX-IRI] for patients with metastatic gastric or colorectal cancer. J Clin Oncol 2005, 23:300s.

    Google Scholar 

  37. Falcone A, Masi G, Murr R, et al.: Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (GONO), 2006 [abstract 199]. Presented at the Gastrointestinal Cancers Symposium. San Francisco, CA; January 26–28, 2006.

  38. Andre T, Boni C, Mounedji-Boudiaf L, etal.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343–2351. Pivotal trial demonstrating the role of FOLFOX in the adjuvant setting.

    Article  PubMed  CAS  Google Scholar 

  39. Wolmark N, Wieand S, Kuebler JP, et al.: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL; May 13–17, 2005.

  40. Saltz LB, Niedzwiecki D, Hollis D, et al.: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol 2004, 22:3500.

    Google Scholar 

  41. Ychou M, Raoul J, Douillard J, et al.: A phase III randomized trial of LV5-FU2+CPT-11 vs. LV5-FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/ FFCD9802) [abstract]. Proc Am Soc Clin Oncol 2005, 23:3s.

  42. Van Cutsem E, Labianca R, Hossfeld D, et al.: Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Proc Am Soc Clin Oncol 2005, 23:LBA8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1275 York Avenue H816, 10021, New York, NY, USA

    Ki Young Chung MD

Authors
  1. Ki Young Chung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonard B. Saltz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ki Young Chung MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, K.Y., Saltz, L.B. Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer. Curr colorectal cancer rep 2, 142–148 (2006). https://doi.org/10.1007/s11888-006-0033-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-006-0033-8

Keywords

Search

Navigation